# TADALAFIL EP

## MEET OUR NEW API

New partnership for exclusive distribution of Tadalafil CEP



Tadalafil

CAS No.: 171596-29-5

ATC Classification: G04BE - Drugs used in erectile dysfunction

## Indications[1,2,3,4]

Tadalafil is a selective phosphodiesterase type 5 (PDE5) inhibitor indicated for the **relief of erectile dysfunction**, **lower urinary tract symptoms secondary to benign prostatic hyperplasia**, and **pulmonary arterial hypertension**.

## Main Pharmaceutical Formulations

Tablets | Capsules | Oral powders | Oral liquids

## Market Evolution in Europe:

| 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| 165 141 057 | 201 287 951 | 241 242 159 | 286 676 287 | 335 614 230 |
| | +22% | +20% | +19% | +17% |

GROWTH 2019-2024 **103%** (units)

*IQVIA

## CEP AVAILABLE

CEP 2025-131

**References: 1.** Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action. Ther Adv Urol. 2015;7(6):303-310. **2.** Andersson KE, de Groat WC, McVary KT, Linton KD, Maggi M, Roehrborn CG, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011;30(3):292-301. **3.** Kloner RA, Schwartz BG. Potential beneficial impacts of tadalafil on cardiovascular diseases. J Chin Med Assoc. 2025;84(?, issue/pagination not specified). **4.** Kalsi J. Phosphodiesterase-5 (PDE5) inhibitors in the treatment of erectile dysfunction: a review. Asian J Pharm Res. 2023;13(1):77-84. **5.** Tadalafil-Loaded Limonene-Based Orodispersible Tablets: Formulation, in vitro Characterization and in vivo Appraisal of Gastroprotective Activity. Pharmaceutics. 2020;12(12):1188. **6.** Development of spray-dried amorphous solid dispersions of tadalafil using glycyrrhizin for enhanced dissolution and aphrodisiac activity in male rats. Drug Dev Ind Pharm. 2020;46(11):1829-1839. **7.** Comparison of tadalafil pharmacokinetics after administration of a new orodispersible film versus a film-coated tablet. Clin Drug Investig. 2018;38(4):355-364. **8.** Boosting tadalafil bioavailability via sono-assisted nano-emulsion-based oral jellies: Box-Behnken optimization and assessment. Pharmaceutics. 2022;14(11):2448.

Want to know more about TADALAFIL?

CONTACT Jovani Valdovinos

jovani.valdovinos@vidara.com